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The incidence of native portal vein thrombosis (PVT) 
in liver transplant recipients has been reported to 
range from 2.1 to 13.8%. We have identified an inordi· 
nately high incidence of PVT in a consecutive series 
of U.S. veterans receiving liver transplants. Between 
October 1989 and February 1994, 88 consecutive U.S. 
veterans received 99 orthotopic liver transplants un· 
der primary Tacrolimus (Prograf, formerly FK506) 
based immunosuppression. A number of clinical fea· 
tures were examined in an effort to identify risk fac· 
tors for PVT and outcome was compared to patients 
without PVT. Native PVT was present in 23/88 (26%) 
patients. All of these patients were male U.S. veterans 
with a mean age of 47 years. When compared to the 65 
patients without PVT, we found no significant differ· 
ence with respect to underlying liver disease, age, 
Childs-Pugh score (mean = 12), UNOS status as de· 
fined prior to April 1995 (95% UNOS 3 or 4), previous 
abdominal surgery, or liver volume. Median blood loss 
for patients with PVT (21 units of packed red blood 
cells) was greater than for those without PVT (14 units, 
P = 0.04). Portal thrombectomy was performed in 11 
patients, 11 patients required mesoportal jump grafts, 
and 1 patient had an interposition graft. Standard 
veno-venous bypass was used in 10 patients with sin· 
gle bypass utilized for the remainder. Actuarial pa. 
tient survival for all patients at 1, 2,and 4 years was 
88,85, and 79%, respectively. There was no significant 
difference in patients with or without PVT. Patients 
with PVT had poorer graft survival than patients with· 
out PVT (86% vs 65%,1 year; 81% vs 65%, 2 years; 81% 
vs 61%,4 years; P = 0.03); however, this was not related 
to technical problems with the portal venous inflow. 
pvr occurred in 26% of U.S. veterans undergoing liver 
transplantation. These patients had significantly 
higher operative blood loss and poorer graft survival. 
The high incidence of postnecrotic cirrhosis in a pre· 
dominantly male group of patients with advanced dis· 
ease, as is evident by the high mean Childs-Pugh score 
and UNOS status, perhaps accounts for our observa· 
tions. "1996 Academic p ........ Inc. 
INTRODUCTION 
Portal vein thrombosis (PVT) and other permuta-
tions of splanchnic venous thromboses, are no longer 
considered relative contraindications to orthotopic liver 
transplantation (OLTX) [1-5]. Historically, the inci-
dence of portal vein thrombosis in cirrhotics has been 
reported to be 11% [61. It is reported to be more common 
in male patients as well as in patients with Budd-
Chiari syndrome and postnecrotic cirrhosis. More reo 
cent studies indicate that the incidence in cirrhosis 
ranges from 0.5 to 21% 16-9J. 
The incidence of native portal vein thrombosis in 
liver transplant recipients has been reported to range 
from 2.1 to 13.8% 11-51. Male patients, patients with 
Laennec's cirrhosis, chronic active viral hepatitis, 
Budd-Chiari syndrome, previous portosystemic shunt, 
hypercoagulable states, trauma, previous portahepatis 
dissection, or postsplenectomy appear to be at a higher 
risk for PVT [1-5, 10-17]. Demographic information 
regarding patients without portal vein thrombosis in 
these series are often lacking and, hence, data regard-
ing other potential risk factors are sparse. A report 
from the University of Pittsburgh identified patients 
with encephalopathy, ascites, variceal bleeding, previ-
ous splenectomy, and a small liver as having a higher 
incidence of PVT 141. 
Under primary Tacrolimus (Prograf, formerly FK506) 
based immunosuppression, we have identified a high 
incidence of native PVT in U.S. veterans undergoing 
OLTX. We have examined a number of clinical features 
in this consecutive series of patients to try and identify 
risk factors for PVT and ascertain the reason for such 
a high incidence in our select patient population. Our 
reconstructive approach for portal revascularization is 
also described. 
MATERIALS AND METHODS 
Patiellt material. At the Veterans Administration Medical Center 
in Pittsburgh, 99 OLTX were performed in 88 patients (87 males, 1 
female) under Tacrolimus (Prograf, formerly FK506) based immuno-
suppression h(?Lween October 1, 1989, and February 28, 1994. Data 
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was obtained from medical records review and from a prospective 
d:1ta base for veterans undergoing primary liver transplantation un-
der Tacrolimus. The immunosuppressive regimen has been described 
previously and the patient's demographics were similar to those in 
the earlier reported series [18]. In this veteran population, 23 pa-
tients (26%) were found to have PVT. All patients were male with a 
mean age of 46.7 years. Thirteen patients had postnecrotic cirrhosis 
secondary to viral hepatitis (hepatitis C [13], hepatitis Band C [2]). 
Six patients had alcoholic cirrhosis and 6 of the aforementioned pa-
tients with viral hepati~is had a history of alcohol abuse. The re-
maining indications for liver transplantation included sclerosing 
cholangitis [2], Wilson disease [1] and alpha-l antitrypsin deficiency 
[1]. Four patients had hepatocellular carcinomas (alcoholic cirrhosis 
[3], Wilson disease [1]) of which two were incidental «2 em). Portal 
vein thrombi were benign in all four patients. The extent of extrahe-
patic portosplanchnic venous thrombosis was classified by the follow-
ing grading system: (a) Grade 1, a partial(mural) thrombosis of the 
main portal trunk extending to or below the confluence with residual 
flow; (b) Grade 2, complete thrombosis of the maih portal trunk not 
extending to the confluence of the superior mesenteric and splenic 
veins; (c) Grade 3, complete thrombosis of the main portal trunk 
extending to the level of the confluence; (d) Grade 4, complete throm-
bosis of the main portal trunk with extension below the confluence. 
Patency of the portal vein was assessed by Doppler ultrasonogra-
phy in all cases. Absence of flow or poor flow was further investigated 
using selective celiac and mesenteric angiography or magnetic reso-
nance imaging if renal function was impaired. Post-transplantation 
evaluation of portal venous inflow was carried out by routine early 
« 7 days) and yearly doppler ultrasonography. Autopsy findings in 
early and late patient deaths were used to determine the patency of 
portal inflow. 
The following clinical parameters were examined as possible risk 
factors for native PVT in liver transplant recipients: etiology of liver 
disease, age, Childs-Pugh score, previous abdominal surgery, UN OS 
status, liver volume (size), presence of ascites, a history of spontane-
ous bacterial peritonitis (SBP), encephalopathy, variceal bleeding, 
and endoscopic sclerotherapy for variceal bleeding. The impact of 
native PVT on patient survival, graft survival, retransplantation 
rate. transfusion requirement, and postoperative infectious morbid-
ity (major bacterial, fungal. and viral) was also examined. 
Statistical analysis. Clinical and laboratory values were entered 
into a database (PROPHET Statistics, BBN Systems and Technolo-
gies, Cambridge MA). Categorical variables (mortality, infection) 
were compared using the x2 test or the Fisher exact test. Ordinal 
values such as UNOS or ChlIds-Pugh score were compared using 
the Mann-Whitney test. Kaplan-Meier survival curves were con-
structed using the date of first transplant as the starting point and 
loss of graft or death as the end points. Survival curves were com-
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RESULTS 
The actuarial survival rates for all 88 patients after 
liver transplantation under primary Tacrolimus-based 
immunosuppression are 88, 85, and 79% at 1, 2, and 4 
years, respectively. 
Patients have been followed for a mean of 38.7 
months (median, 41.5 months; range, 13 to 64 months). 
Patient survival did not differ significantly in patients 
with or without PVT (83% vs 88%, 1 year; 83% vs 84%, 
2 years; 77% vs 81%, 4 years) (Fig. 1). Patients with 
PVT had poorer graft survival with a larger number of 
early graft losses (Fig. 2) (85% vs 65%, 1 year; 81% vs 
65%, 2 years; 81% vs 61%, 4 years; P = 0.03)_ These 
graft losses were not a consequence of technical prob-
lems related to portal venous inflow. 
Eight patients (39%) had undergone previous in-
traabdominal surgery. Procedures included an explor-
atory laparotomy for trauma, distal splenorenal shunt, 
total colectomy, cholecystectomy [31, and appendec-
tomy 121. All patients had Childs-Pugh class Cliver 
disease (mean score 12.4). Ten patients were in the 
intensive care unit (UNOS status 4) before trans-
plantation and the remaining 13 patients were hospi-
talized (UNOS 3). Liver size and age were similar in 
those with and without PVT. Characteristics of the pa-
tients with and without PVT are shown in Table 1. 
Complications of Portal Hypertension and Portal Vein 
Thrombosis 
The association of various consequences of portal hy-
pertension (ascites, spontaneous bacterial peritonitis, 
encephalopathy, variceal bleeding:!: sclerotherapy) in 
patients with or without PVT was examined (Table 2). 
No statistically significant differences between the two 
groups were observed. 
Radiologic Studies 
Routine pretransplant Doppler ultrasonography 
showed a patent portal venous system in 17 of 23 pa-
.; 
, 
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TABLE 1 
Risk Factors for Native Portal Vein Thrombosis 








































































a Patients with both a history of alcohol use and viral hepatitis (6! 
24 with PVT, 13/65 without PVT). 
tients. Six of these patients had incomplete thrombosis 
(Grade 1) with residual flow discovered at surgery or 
with angiography [2], while the remainder had com-
plete obstruction (11 false negative studies). We rou-
tinely perform pretransplant angiography when ultra-
sonography fails to demonstrate portal flow or there is 
questionable (low) flow. In cases where hepatofugal 
flow is demonstrated, angiography is, in general, re-
served for those with low flow. Selective celiac and mes-
enteric angiography documented complete obstruction 
in 6 patients, while two studies showed small patent 
portal veins with mural thrombosis and spontaneous 
portosystemic shunts. Six intraoperative portograms 
were carried out to define better the splanchnic venous 
return for reconstruction. Magnetic resonance imaging 
studies indicated the portal venous system to be falsely 
patent in 2 patients, while one study indicated com-
plete thrombosis in a patient with marginal flow shown 
by ultrasonography (2/3 false negative studies). 
Surgical Approach 
The extent of portal-splanchnic thrombosis and re-
constructive approach for this series of patients is 
shown in Table 3. The importance of routine procure-
ment of iliac vessels was established in the early days 
of liver' transplantation [19]. Procurement and vein 
grafting techniques have been well described and these 
were applied in this case series [10-15, 20]. Intraopera-
tive assessment with dissection of the portal vein to 
the confluence of the superior mesenteric and splenic 
veins revealed incomplete thrombosis (Grade 1) of the 
main portal trunk extending to or below the confluence 
in 6 cases. Thrombectomy was carried out in all 6 cases 
with end-end anastomotic reconstruction. In 4 pa-
tients with complete thrombosis not extending to the 
confluence (Grade 2), thrombectomy was also utilized 
with end-end reconstruction. Extension to or below 
the confluence with complete thrombosis (Grades 3 and 
4) was noted in the remainder with reconstruction us-
ing allogeneic iliac vein mesoportaljump grafts (trans-
mesocolic) (Fig. 3) in 11 patients, thrombectomy with 
end to end anastomosis in 1 patient, and an interposi-
tion graft to the confluence in 1. Two patients had spon-
taneous splenorenal shunts, however, portal flow via 
the iliac vein grafts was excellent and ligation of the 
shunt and collaterals was not necessary. Post-trans-
plant allograft function was excellent in both patients. 
Transplantation in patients with PVT was associated 
with a significantly greater blood loss with a median 
use of21 units of packed red blood cells versus 14 units 
in patients without PVT (P = 0.04). Standard veno-
venous bypass was used in 10 patients (after thrombec-
tomy) with single bypass utilized in the remainder. 
Mortality, Morbidity, and Retransplantation 
There were five patient deaths (21%). Operative 
deaths (within the first 30 days) occurred in two pa-
tients and 1 patient died at 70 days. One operative 
death was the result of severe coagulopathy, massive 
transfusion, and myocardial failure with accompanying 
intractable dysrhythmias postoperatively. The other 
patient experienced primary graft nonfunction in the 
first two allografts with documented heavy deposition 
of complement and immunoglobulin consistent with 
hyperacute rejection. This patient expired after a third 
attempt at transplantation with a myocardial in-
farction followed by multiple systems organ failure. 
TABLE 2 
Incidence of Portal Vein Thrombosis and 
Complications of Portal Hypertension 
Condition PVT (/I = 23) No PVT (n = 65) 
Encephalopathy 
(Grades 2-4) 11 (48%) 27 (41%) 
Ascites 17 (74%) 40 (61%) 
Spontaneous 
bacterial 
peritonitis 5 (22%) 23 (35%) 
Variceal bleed 5 (22%) 15 (23%) 
Sclerotherapy! 
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TABLE 3 
Extent of Portal-Splanchnic Thrombosis and M.ethod of Reconstruction 


















"Grade 1, mural thrombosis of main portal trunk (:': extension below) with residual flow; Grade 2, complete thrombosis of the main portal 
trunk not extending to the confluence; Grade 3, complete thrombosis of the main portal trunk extending to the confluence; Grade 4, complete 
thrombosis of the main portal trunk with extension below the confluence. 
b End-end anastomosis. 
The patient death at 70 days was the result of a family 
decision to withdraw support. One late patient death 
at 26 months was the result of allograft failure second-
ary to recurrent hepatitis B (DNA positive). A second 
late death (9 months) from sepsis occurred after re-
transplantation. Patent portal venous inflow was docu-
mented in all five patients at autopsy. 
Dialysis-dependent renal failure was seen in five pa-
tients. Two patients required long-standing hemodialy-
sis (> 1 month) pretransplant with renal failure resolv-
ing postoperatively in one. Hemodialysis was tempo-
rary in the remainder. Exploratory laparotomy for 
bleeding was required in one patient. Two patients had 
clinical peritonitis warranting exploration with pri-
mary peritonitis found in one patient and secondary 
peritonitis due to patchy areas of necrosis found in the 
small intestine of the other. Biliary complications in-
cluded a small contained bile leak from a choledochojej-
unostomy and biliary cast formation both requiring re-
construction. This surgical morbidity was unrelated to 
portal venous inflow or vascular anastomotic complica-
tions. The patient with biliary cast formation died with 
recurrent hepatitis B (see above) and the remainder 
are all alive and well. Post-transplant surgical morbid-
ity was similar in patients with and without PVT. 
The mean number of major infections (bacterial or 
fungal) in the PVT group did not differ significantly 
from those without PVT. The incidence of CMV disease 
was similar in both groups at 17% in patients with PVT 
and 12% in those without (Table 4). 
Retransplantation was necessary in six patients 
(26%). Four received a second allograft, while one pa-
tient received three grafts. Early retransplantation 
«7 days) was performed for primary nonfunction in 
four patients with satisfactory function of the new allo-
graft in three patients. The fourth patient in this early 
retransplant group experienced repeated graft non-
function with evidence of hyperacute rejection. A fifth 
patient was retransplanted at 95 days because of sig-
nificant arterial stenosis at the level of the bifurcation 
of the right and left hepatic arteries. Reconstruction of 
the arterial inflow to the first allograft was necessary 
at this high level because of an intimal dissection in 
the donor artery. The sixth patient required retrans-
plantation at 8.5 months for chronic rejection and died 
of staphylococcal sepsis and anoxic brain injury 29 days 
after retransplantation with normal graft function. 
TABLE 4 
Infectious Morbidity after OLTx and Native PVT 
Infection PVT (Il = 23) No PVT (n = 65) P value 
Viral 
CMV shedding 9 (39%) 20 (31%) 0.4 
CMV disease 4 (17'7r,,) H <12%) 0.5 
Major bacterial" 10 (43%) 18 (28%) 0.16 
Fungal (invasive) 1 (4%) 7 (11%) 0.4 
FIG. 3. Transmesocolic allogeneic iliac vein meso-portal jump " Defined as bacteremia, intraabdominal abscess, wound infection, 
graft. peritonitis, c. difficile colitis, cholangitis. 
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Only four patients (6%) required retransplantation in 
the non-PVT group (P = 0.02). 
DISCUSSION 
AB a result of refinements in techniques and experi-
ence with complex portal venous reconstruction, the 
presence of thrombus in the portal vein and its tribu-
taries is not a contraindication for liver transplantation 
[1-5]. Nonetheless, few would argue that these pa-
tients represent a greater technical challenge. 
We know historically that mortality is ensured 
should we fail to establish portal venous inflow in the 
transplanted liver [21]. It is mandatory, therefore, to 
document patency of the portal system prior to trans-
plantation. Like most centers, we rely.on duplex ultra-
sonography which is a simple, noninvasive technique 
[22-24]. Although others have reported a high degree 
of sensitivity for PVT with duplex scans, we have not 
had the same experience [lJ. As a result, our threshold 
for pursuing further imaging studies such as selective 
splanchnic angiography has lessened. We reserve the 
use of intraoperative portography for cases of unex-
pected complete (Grades 2-4) PVT in which the anat-
omy is not clear. 
It has been observed that PVT appears to be more 
common in males and in patients with Laennec's cir-
rhosis or chronic active hepatitis (CAH) [1, 2, 17J. We 
did not find any statistically significant difference be-
tween our patients with and without PVT and their 
underlying etiology of liver disease. It is notable, how-
ever, that we have a very high incidence of post necrotic 
cirrhosis (Laennec's +/- CAH)(84% in patients with 
PVT, 86% in patients without PVT). This is perhaps 
one factor that may account for the high overall inci-
dence of PVT in our veteran population. It has been 
hypothesized that the higher rate of PVT in patients 
with postnecrotic cirrhosis may be attributable to a 
higher impedance of flow through what are generally 
smaller, shrunken livers. Although a previous report 
found liver volume (size) to be an important risk factor 
[4], we did not find any significant difference in liver 
volume between the two groups. Consistent with the 
higher impedance to flow hypothesis is our observation 
of severe portal hypertension in the vast majority of 
our patients with PVT (only two had spontaneous por-
tosystemic shunts with decompression). 
Although we had a relatively high incidence of pre vi-
ous abdominal surgery in both groups, we did not have 
an appreciable number of patients with previous sple-
nectomy or portosystemic shunt surgery to allow for 
meaningful statistical analysis of these specific risk 
factors previously alluded to [2, 4, 7]. Previous upper 
abdominal surgery certainly added to the technical 
challenge in our patients with PVT and not unexpect-
edly the mean transfusion requirement was signifi-
cantly higher in this group (P = 0.04). 
Other risk factors for PVT that reflect severity of 
disease were also examined. We did not find any differ-
ence in the two groups with respect to UNOS status 
(>95% status 3-4), Childs-Pugh score (mean = 12 in 
both), or complications of portal hypertension including 
consequences of endoscopic variceal sclerotherapy in 
contrast to the findings of Nonami et aZ. and others [4, 
17J. The incidence of encephalopathy, ascites, and SBP 
was higher overall in our series of patients and these 
factors coupled with a high mean Childs-Pugh score 
and UNOS status simply reflect a high risk group of 
patients overall with advanced disease. 
Post-transplantation infectious morbidity was exam-
ined in both groups with expectations that major bacte-
rial or invasive fungal infections were more prevalent 
in patients with PVT [2]. With the higher retrans-
plantation rate in our patients with PVT, a higher rate 
of infections, complications, and mortality are expected 
f25, 261. We did not observe any statistically significant 
differences in viral, major bacterial, or fungal infec-
tions between the two groups in .our series, although 
bacterial infections were observed more frequently in 
patients with PVT (P = 0.16). This is surprising but, 
nevertheless, consistent with our previously published 
observations in which our overall incidence of major 
bacterial infections was only 39% (27). 
Our surgical approach to patients with PVT is depen-
dent upon the determination of the extent of splanchnic 
venous thrombosis and the degree of portal hyperten-
sion and collaterization in the portahepatis and peri-
pancreatic region. We concur with Stieber et aZ. (1) and 
Langnas et al. (2) and try to avoid extensive peripan-
creatic dissection, especially in patients with Grades 
3-4 PVT. We have a low threshold to employ transme-
socolic mesoportaljump grafts, and we believe that this 
has resulted in less morbidity (no cases of pancreatitis) 
in patients with advanced portal-splanchnic thrombo-
sis. With non occlusive disease or less extensive occlu-
sive (Grade 2) PVT, we prefer thrombectomy with end 
to end reconstruction or the use of an interposition 
graft if necessary. 
The overall actuarial 1-, 2-, and 4-year survival rates 
were 88, 85, and 79%, respectively. Survival in patients 
with PVT were slightly less than those without at 1 
year (83% with PVT, 88% no PVT); however, this was 
not statistically significant. Patients with PVT did have 
significantly diminished graft survival; however, the 
majority (4/6) of patients requiring retransplantation 
were rescued and are currently alive and well. There 
were no episodes of graft loss related to portal venous 
inflow and we have not had any cases of portal throm-
bosis after reconstruction (iliac vein graft or otherwise). 
The higher retransplantation rate and incidence ofpri-
mary nonfunction in patients with PVT has been ob-
served by others and has been attributed to the charac-
teristically difficult intra- and postoperative course [2]. 
Our results are similar to those of Langnas et aZ. and 
others 11-3, 171 and adds further testimony to the sal-
vageability of high risk patients in need of liver trans-
plantation [28, 29 J. It is clear from this report that 
U.S. veterans are a skewed patient population when 
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UNOS; however, this did not adversely impact upon 
patient survival to a significant degree [30, 31]. 
In summary, although we could not identify any sig-
nificant risk factors for native PVT in our series of 
patients, it would appear that the group as a whole has 
a high prevalence of many of the risk factors alluded 
to in previously reported series [1-5, 17]. Our patient 
population is predominantly male with a high inci-
dence of postnecrotic cirrhosis and advanced disease 
(UNOS 3-4, high mean Childs-Pugh Score). Perhaps 
these features account for our observed high incidence 
of PVT in U.S. veterans undergoing OLTX.. A patient, 
flexible approach to portal revascularization in these 
patients can yield quite acceptable survival and mor-
bidity rates. 
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